Through journaling and connecting with my faith, I was able to embrace everything I was thinking and feeling during colon ...
The recent FDA approval of Lazcluze plus Rybrevant for EGFR-mutant non-small cell lung cancer is a “big deal” for patients, ...
Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis.